Tudorza Pressair inhalation powder
Breath-activated dry powder inhaler indicated for long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and emphysema
Commercially Insured Patients: Eligible for 100% off their first inhaler if co-pay is more than $25. Cash Patients: Up to $100 savings on each out-of-pocket cost more than $25 for each prescription. Offer is good for 12 inhalers.
Savings Expires: 12/31/2016